Phaarmasia Ltd
Incorporated in 1981, Phaarmasia Ltd is engaged in manufacturing and marketing of Cosmetics, Oral Contraceptive Pills (OCP) and Combipack with Iron Tablets
- Market Cap ₹ 23.4 Cr.
- Current Price ₹ 34.2
- High / Low ₹ 64.5 / 23.6
- Stock P/E
- Book Value ₹ 12.8
- Dividend Yield 0.00 %
- ROCE -16.5 %
- ROE -16.7 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Debtor days have improved from 80.9 to 46.6 days.
Cons
- Stock is trading at 2.67 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 4.10% over past five years.
- Company has a low return on equity of -10.7% over last 3 years.
- Company's cost of borrowing seems high
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
15.16 | 12.30 | 13.68 | 14.33 | 18.97 | 23.97 | 19.93 | 16.20 | 16.88 | 27.42 | 30.59 | 24.37 | 22.95 | |
14.32 | 11.35 | 12.94 | 14.19 | 18.31 | 23.24 | 19.11 | 16.26 | 18.62 | 28.97 | 31.41 | 26.38 | 25.05 | |
Operating Profit | 0.84 | 0.95 | 0.74 | 0.14 | 0.66 | 0.73 | 0.82 | -0.06 | -1.74 | -1.55 | -0.82 | -2.01 | -2.10 |
OPM % | 5.54% | 7.72% | 5.41% | 0.98% | 3.48% | 3.05% | 4.11% | -0.37% | -10.31% | -5.65% | -2.68% | -8.25% | -9.15% |
0.00 | 0.07 | 0.01 | 0.58 | 0.53 | 0.60 | 0.58 | 0.89 | 0.47 | 0.52 | 0.66 | 0.75 | 0.91 | |
Interest | 0.02 | 0.03 | 0.01 | 0.01 | 0.04 | 0.04 | 0.04 | 0.01 | 0.00 | 0.04 | 0.04 | 0.02 | 0.04 |
Depreciation | 0.38 | 0.76 | 0.50 | 0.44 | 0.47 | 0.46 | 0.40 | 0.34 | 0.29 | 0.36 | 0.34 | 0.32 | 0.30 |
Profit before tax | 0.44 | 0.23 | 0.24 | 0.27 | 0.68 | 0.83 | 0.96 | 0.48 | -1.56 | -1.43 | -0.54 | -1.60 | -1.53 |
Tax % | 18.18% | 39.13% | 83.33% | 37.04% | 16.18% | 6.02% | 44.79% | 33.33% | -1.28% | -11.89% | -5.56% | -0.62% | |
0.35 | 0.14 | 0.04 | 0.16 | 0.57 | 0.78 | 0.54 | 0.31 | -1.55 | -1.26 | -0.52 | -1.59 | -1.60 | |
EPS in Rs | 0.51 | 0.21 | 0.06 | 0.23 | 0.83 | 1.14 | 0.79 | 0.45 | -2.27 | -1.85 | -0.76 | -2.33 | -2.35 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 7% |
5 Years: | 4% |
3 Years: | 13% |
TTM: | -28% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -1% |
TTM: | -5433% |
Stock Price CAGR | |
---|---|
10 Years: | 11% |
5 Years: | -1% |
3 Years: | 10% |
1 Year: | -33% |
Return on Equity | |
---|---|
10 Years: | -2% |
5 Years: | -8% |
3 Years: | -11% |
Last Year: | -17% |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 6.83 | 6.83 | 6.83 | 6.83 | 6.83 | 6.83 | 6.83 | 6.83 | 6.83 | 6.83 | 6.83 | 6.83 |
Reserves | 0.62 | 6.28 | 5.04 | 4.83 | 5.20 | 5.99 | 6.58 | 6.83 | 5.23 | 3.98 | 3.47 | 1.91 |
0.00 | 0.11 | 0.09 | 0.07 | 0.22 | 0.19 | 0.08 | 0.05 | 0.03 | 0.27 | 0.14 | 0.01 | |
5.91 | 6.17 | 6.74 | 7.81 | 9.67 | 20.25 | 20.11 | 8.20 | 9.12 | 17.34 | 21.01 | 12.81 | |
Total Liabilities | 13.36 | 19.39 | 18.70 | 19.54 | 21.92 | 33.26 | 33.60 | 21.91 | 21.21 | 28.42 | 31.45 | 21.56 |
10.51 | 15.61 | 14.11 | 13.74 | 14.18 | 13.80 | 13.40 | 13.06 | 12.76 | 12.79 | 12.48 | 12.32 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
2.85 | 3.78 | 4.59 | 5.80 | 7.74 | 19.46 | 20.20 | 8.85 | 8.45 | 15.63 | 18.97 | 9.24 | |
Total Assets | 13.36 | 19.39 | 18.70 | 19.54 | 21.92 | 33.26 | 33.60 | 21.91 | 21.21 | 28.42 | 31.45 | 21.56 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.16 | 0.48 | 0.28 | -0.08 | 0.88 | 0.06 | 0.08 | 0.25 | -0.18 | 0.65 | 0.11 | 0.00 | |
-0.17 | -0.34 | -0.28 | -0.18 | -0.92 | -0.10 | 0.00 | 0.00 | 0.01 | -0.01 | 0.00 | -0.12 | |
0.00 | 0.12 | 0.16 | -0.02 | 0.08 | 0.04 | -0.11 | -0.02 | 0.00 | -0.16 | -0.16 | -0.15 | |
Net Cash Flow | -0.01 | 0.26 | 0.17 | -0.29 | 0.04 | 0.00 | -0.03 | 0.23 | -0.17 | 0.48 | -0.06 | -0.27 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 47.67 | 47.78 | 77.64 | 90.68 | 72.92 | 179.07 | 225.63 | 96.21 | 68.98 | 99.97 | 96.05 | 46.58 |
Inventory Days | 13.98 | 80.49 | 11.77 | 55.86 | 43.40 | 134.51 | 124.67 | 65.84 | 111.66 | 103.36 | 126.07 | 57.39 |
Days Payable | 57.90 | 184.68 | 216.27 | 292.87 | 249.28 | 403.08 | 374.43 | 166.48 | 214.10 | 268.79 | 297.81 | 224.33 |
Cash Conversion Cycle | 3.74 | -56.42 | -126.86 | -146.33 | -132.96 | -89.49 | -24.13 | -4.43 | -33.46 | -65.47 | -75.69 | -120.35 |
Working Capital Days | -71.75 | -79.23 | -64.04 | -43.05 | -33.67 | -12.79 | 6.78 | 7.66 | -17.30 | -39.00 | -42.60 | -71.29 |
ROCE % | 6.15% | 2.52% | 1.99% | 2.36% | 6.01% | 6.65% | 7.55% | 3.60% | -12.09% | -12.00% | -4.65% | -16.47% |
Documents
Announcements
-
Integrated Filing (Financials) For The Quarter Ended 30Th June, 2025
13 Aug - Phaarmasia Ltd reports Q1 FY26 audited profit of Rs.27.02 lakhs, no loan defaults, per SEBI norms.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
12 Aug - News paper Advertisement of the Un-audited financial statement for the quarter ended 30 june 2025
- Financial Results For The Quarter Ended 30Th June 2025 - Regulation 33(3) (A) Of SEBI (LODR) Regulations, 2015. 11 Aug
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 11Th August 2025
11 Aug - Approved Q1 unaudited results, AGM date fixed, director reappointed with increased remuneration.
-
Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Monday, 11Th August, 2025 For Approval Of Unaudited Financial Statement For The Quarter Ending June 30, 2025 And Other Ancillary Items.
7 Aug - Board meeting on Aug 11 to approve Q1 results, audit reports, and finalize 44th AGM details.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Overview:[1][2]
Company provides various therapeutic dosage combinations for Ministry of Health & Family Welfare and also for exports. In FY20, company became a Sick Industrial Company under SICA and was referred to BIFR.